Wordt geladen...
Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, importa...
Bewaard in:
| Gepubliceerd in: | J Diabetes Res |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Hindawi Publishing Corporation
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4709665/ https://ncbi.nlm.nih.gov/pubmed/26839899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/8352957 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|